Lifecore Biomedical (LDE) Stock Overview
Operates as an integrated contract development and manufacturing organization in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
LDE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Lifecore Biomedical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.20 |
| 52 Week High | US$7.45 |
| 52 Week Low | US$4.00 |
| Beta | 0.62 |
| 1 Month Change | -8.15% |
| 3 Month Change | -8.15% |
| 1 Year Change | 48.33% |
| 3 Year Change | -29.55% |
| 5 Year Change | n/a |
| Change since IPO | 24.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| LDE | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 7.8% | 15.0% | 2.7% |
| 1Y | 48.3% | -13.4% | 14.6% |
Return vs Industry: LDE exceeded the German Life Sciences industry which returned -13.4% over the past year.
Return vs Market: LDE exceeded the German Market which returned 14.5% over the past year.
Price Volatility
| LDE volatility | |
|---|---|
| LDE Average Weekly Movement | 7.7% |
| Life Sciences Industry Average Movement | 6.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 12.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: LDE's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: LDE's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1965 | 406 | Paul Josephs | www.lifecore.com |
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of hyaluronate acid (HA) in bulk form, as well as formulated and filled syringes, cartridges, and vials for injectable products used in treating a range of medical conditions and procedures. Its product development services include analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and production of materials for clinical studies.
Lifecore Biomedical, Inc. Fundamentals Summary
| LDE fundamental statistics | |
|---|---|
| Market cap | €222.76m |
| Earnings (TTM) | -€37.78m |
| Revenue (TTM) | €109.77m |
Is LDE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LDE income statement (TTM) | |
|---|---|
| Revenue | US$128.87m |
| Cost of Revenue | US$88.57m |
| Gross Profit | US$40.30m |
| Other Expenses | US$84.66m |
| Earnings | -US$44.36m |
Last Reported Earnings
May 25, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.18 |
| Gross Margin | 31.27% |
| Net Profit Margin | -34.42% |
| Debt/Equity Ratio | 275.0% |
How did LDE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/05 14:33 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/05/25 |
| Annual Earnings | 2025/05/25 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lifecore Biomedical, Inc. is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Petusky | Barrington Research Associates, Inc. |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| Brian Holland | D.A. Davidson & Co. |